XYNTHA (recombinant factor VIII) Patient Assistance Program
Don’t let the high cost of brand factor VIII replacement disrupt your hemophilia A treatment. We help eligible patients access Xyntha (recombinant factor VIII) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Xyntha (moroctocog alfa, recombinant factor VIII) is FDA-approved for hemophilia A — bleeding control, perioperative management, prophylaxis. Standard half-life recombinant FVIII without albumin.
- Without assistance, Xyntha costs commonly run approximately $15,000–$50,000+ per month depending on dose and weight.
- Through AffordMyPrescriptions, qualifying patients can access Xyntha for a flat $69.95 per month.
- Other rFVIII products: Advate (octocog alfa), Kovaltry, Eloctate (rFVIIIFc — extended half-life), Adynovate (PEGylated), Jivi, Esperoct (extended half-life). Non-replacement therapy: emicizumab (Hemlibra — SC weekly to monthly, FVIII mimetic for prophylaxis). Gene therapy: Roctavian (one-time treatment).
What Is Xyntha Prescription Assistance Program?
Xyntha PAP for hemophilia A patients.
Eligibility, hematology coordination.
AffordMyPrescriptions eliminates that burden. $69.95/month advocacy.
Pharmacy Price Comparison
- Xyntha $15,000–$50,000+/month:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Specialty Pharmacy | ~$30,000+ | Save substantially |
| Hospital pharmacy | ~$50,000+ | Save substantially |
| Extended half-life products | $30,000+ | Less frequent dosing |
| Hemlibra (alternative) | $30,000+ | Different mechanism |
PAP-approved | $0 | Manufacturer PAP |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Xyntha Prescription Program?
PAP critical at this price. Hemlibra (emicizumab) alternative — subcutaneous, more convenient than factor infusions.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Xyntha:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Coupon cards expire and require constant renewal
Still $15,000–$50,000+ per month per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Xyntha assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Xyntha Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Understanding Xyntha:
Xyntha is recombinant factor VIII for hemophilia A — X-linked F8 gene mutations causing FVIII deficiency. Without treatment, recurrent bleeds cause arthropathy and life-threatening hemorrhage. Modern prophylaxis dramatically improves outcomes.
How Xyntha Works:
FVIII is essential coagulation factor — cofactor for FIXa in intrinsic pathway activating FX. Hemophilia A severity correlates with FVIII activity (<1% severe, 1–5% moderate, 5–40% mild).
Xyntha is recombinant FVIII produced in CHO cells (B-domain deleted, albumin-free). Standard half-life (~12 hours) requires every-2–3-day IV infusion for prophylaxis. Extended half-life products (Eloctate, Adynovate, Jivi, Esperoct) allow less frequent dosing.
Form and use:
Xyntha IV infusion every 2–3 days for prophylaxis. Self-infused at home after training.
Generic availability:
No biosimilar. Other rFVIII: Advate, Kovaltry, Eloctate (extended half-life), Adynovate, Jivi, Esperoct. Plasma-derived FVIII: Humate-P, Alphanate. Hemlibra (emicizumab — bispecific antibody mimicking FVIII function, SC injection weekly to monthly) — game-changer for hemophilia A prophylaxis especially with inhibitors. Roctavian (valoctocogene roxaparvovec) — gene therapy, one-time $2.9M.
Warnings:
Hypersensitivity reactions, inhibitor development (anti-FVIII antibodies — ~30% of severe hemophilia A patients; immune tolerance induction or bypassing agents needed), thrombotic events (rare with combined factor concentrate use).
FAQ (Frequently Asked Questions)
Cost ?
$15,000–$50,000+/month. Annual $200,000–$600,000+. Insurance critical.
Xyntha vs other rFVIII?
All similar efficacy. Choice often by physician preference, prior response, insurance. Extended half-life products less frequent dosing.
Hemlibra (emicizumab)?
Bispecific antibody mimicking FVIII function. SC injection weekly to monthly (vs every-2–3-day IV factor). Effective for prophylaxis including in patients with inhibitors. Major advance in hemophilia A care.
Gene therapy?
Roctavian (valoctocogene roxaparvovec) — AAV5 gene therapy delivering F8 to liver. One-time IV ~$2.9M but potentially eliminates need for ongoing factor replacement. Available at specialized centers.
Inhibitors?
~30% of severe hemophilia A develops anti-FVIII inhibitors. Immune tolerance induction or bypassing agents (NovoSeven, FEIBA). Hemlibra particularly useful.
Denied?
Other rFVIII products with PAPs. Hemlibra. Hemophilia Foundation. Gene therapy referral.
Take Control of Your Medication Costs
If facing Xyntha cost, manufacturer PAP and Hemlibra alternative help. Check eligibility today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.